Skip to content
Calculator
Guide

Peptide cycling: is 'on/off' science or folklore?

Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board

A person writing on a desk calendar
Photo by RDNE Stock project on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • We found no trial testing an on/off schedule for any peptide.
  • Receptor desensitisation is real; in the growth hormone studies, whether it happened depended on dose and frequency, and the pituitary was not exhausted.
  • Approved peptide medicines are dosed continuously; MK-677 raised IGF-1 after a year of daily dosing.
  • Where an approved label sets a stopping rule, it rests on a measurement, such as IGF-1 for tesamorelin, not on a calendar.

Where cycling came from

On/off schedules quoted for peptides, such as eight weeks on and four off, resemble the cycles used with anabolic steroids, but we found no peptide study that proposed or tested one. The mechanism usually offered for them is receptor desensitisation, and the evidence about it points somewhere else.

What receptor desensitisation actually is

Receptors that peptides act on are mostly G-protein-coupled receptors. A 1997 review describes how cellular responses to their agonists are usually attenuated rapidly, through removal of the agonist, receptor phosphorylation and desensitisation, and endocytosis, with recycling of internalised receptors helping responses recover; down-regulation, a loss of the cell's receptors, is a further form that occurs during continuous, long-term exposure and may contribute to drug tolerance (review) 1.

So 'tolerance' covers several different processes, some fast and some slow. None of them, in the review, comes with a calendar of weeks on and weeks off; what they depend on is how continuous the exposure is 1.

The growth hormone axis: the clearest evidence

The most direct human experiment is old and good. Ten normal men received a six-hour infusion of either saline or GHRH, then a large challenge dose of GHRH or an insulin injection. The growth hormone response to the challenge dose of GHRH was greater after the saline infusion than after the GHRH infusion, so the somatotrophs had become partly refractory. But the response to insulin-induced low blood sugar, a different stimulus, was greater after the GHRH infusion, and the largest secretion of all came during GHRH infusion followed by insulin, showing pituitary reserve had not been depleted (human study) 2.

Two conclusions follow, and they pull in different directions from the cycling story. The cells do become less responsive to continued stimulation by the same signal. And they are not exhausted: the hormone is still there and another stimulus releases it.

Compound classWhat continuous or repeated exposure doesDoes an 'off week' follow from the evidence?
GHRH and analogues (tesamorelin, sermorelin, CJC-1295)Continuous GHRH infusion made somatotrophs partly refractory to GHRH within hours, while pituitary reserve stayed intactNo cycling schedule has been tested; approved tesamorelin is taken daily, continuously
Ghrelin-receptor secretagogues (GHRP-2, ipamorelin, MK-677)Whether the response fades on chronic dosing depended on dose and frequency; MK-677 raised IGF-1 at 6 weeks and still at 12 monthsNot tested; the long trials dosed daily throughout
GnRH agonistsProlonged activation desensitises the pituitary and suppresses gonadotrophins, which is the intended effect of the drugsContinuous dosing is the point; interrupting it defeats the treatment
GLP-1 receptor agonistsApproved products are taken continuously; stopping is followed by weight regainNo; labels describe continued use
BPC-157, TB-500 and other research peptidesNo human pharmacology to describeThere is nothing to cycle against

Secretagogues over weeks

Chronic dosing has been studied too. Normal younger and older men and women received GHRP-2, GHRH or both for 7 to 30 days; chronic administration of either peptide converted the additive response to the combination into a synergistic one, and the authors concluded that whether the growth hormone response desensitises during chronic administration depends in part on the dosage and frequency of administration (human study) 3. Dose and frequency, again, not calendar blocks. Note also what the study measured: the shape of the response to a combination, not a loss of response over a month.

In rat pituitary cells, in a study by Merck scientists, GHRP-2 and GHRP-6 desensitised the cells to each other but not to GHRH (laboratory study) 4. That is a mechanistically interesting point for anyone stacking two secretagogues of the same class: swapping one for another within the class is not a reset.

The longest human data come from MK-677. In a 12-month Merck trial in 563 people with Alzheimer's disease, 416 of whom completed it, serum IGF-1 rose 60.1% at six weeks and was still 72.9% above baseline at 12 months of continuous daily dosing (randomised trial) 5. The drug failed its clinical endpoints in that trial, but as a measure of whether the axis simply stops responding, a year of daily dosing with IGF-1 still elevated is the answer.

Where desensitisation is the point

One class shows how powerful desensitisation can be when it is pursued deliberately. GnRH receptors are G-protein-coupled receptors on pituitary gonadotrophs, and prolonged activation by GnRH leads to desensitisation and suppressed gonadotrophin secretion, which is the primary mechanism of action of agonist analogues (review) 6. Here continuous exposure is the treatment, and taking time off would defeat it.

Our kisspeptin and gonadorelin comparison covers how the pattern of GnRH-axis stimulation is handled in practice.

How approved peptide medicines are actually dosed

The labels of approved peptide medicines set no off-weeks. Tesamorelin, a GHRH analogue, is injected once daily 7, and semaglutide for weight loss once weekly 8. The extension of the STEP 1 trial showed what stopping semaglutide does: 327 participants who had lost a mean 17.3% of body weight over 68 weeks regained 11.6 percentage points of it in the year after withdrawal, and most of the cardiometabolic improvements drifted back towards baseline (exploratory extension of a randomised trial, with Novo Nordisk authors) 9. Our half-life and dosing guide sets out the intervals each label specifies and why they differ.

What labels do contain is monitoring and stopping rules. The EGRIFTA WR label, for example, says to monitor IGF-1 during therapy and to consider stopping in patients with persistent elevations 7. Those are clinical decisions based on measurements, not a calendar. Our regulatory tracker records which peptides have an approved label at all, which is the first thing to establish before any schedule is discussed.

Tolerance, tachyphylaxis and what people actually notice

A reason often given for cycling is that the effect faded. That observation can be real without receptor desensitisation being the cause, and where nothing was measured, a fading effect is an impression rather than a finding.

The growth hormone evidence is a useful corrective here because it was measured. The response to a repeat GHRH challenge fell, yet the pituitary released more hormone than ever when a different stimulus was applied 2, and a year of daily MK-677 still held IGF-1 well above baseline 5. If an axis were simply becoming exhausted, neither result would look like that.

The research peptides, where there is nothing to cycle against

For BPC-157, TB-500 and most of the compounds cycling schedules are quoted for, there is no human pharmacology to desensitise. Our BPC-157 entry records what has and has not been studied. A cycle length for a compound with no established human dose, half-life or receptor target is a number without a referent: it cannot be right or wrong because nothing was measured.

Stimulating is not the same as suppressing

Growth hormone secretagogues stimulate the body to release its own hormone through the pituitary, which is why the 1986 infusion study could show the gland still holding releasable hormone after its cells had become partly refractory to that particular signal 2.

GnRH agonists are the case where a peptide does suppress downstream hormones, and there suppression is the intended effect of continuous dosing 6. Where a peptide does suppress something, that is a reason for medical supervision and monitoring, not for a self-scheduled break.

What a scheduled break can cost

Framing use as cycles also hides a cost. For an approved medicine taken for a condition, an unprescribed break is simply an interruption of treatment, and the STEP 1 extension shows how quickly the benefit unwinds 9. For an unapproved compound, a cycle schedule can give a false sense that the plan is grounded in something, when the dose, the interval and the break are all invented.

Our reconstitution guide covers where dosing mistakes happen with new vials.

Better questions than 'how long should I cycle?'

  • What is the dosing interval that the evidence or label supports, since frequency is what the desensitisation data concern?
  • Is there a measurement that tells me whether this is working or overshooting, such as IGF-1 for growth hormone secretagogues?
  • What are the stopping rules, meaning the side effects or results that should end use regardless of schedule?
  • Is the compound approved for anything at all, and if not, what am I scheduling?

The bottom line

Cycling peptides is folklore in its specifics and half-true in its premise. Receptors do desensitise, and the growth hormone axis demonstrates it clearly, but in the studies above it depended on dose and frequency and did not exhaust the gland. What the research supports is attention to dose and frequency, and measurements where they exist. What it does not support is any particular number of weeks on followed by any particular number off, because no study we found has tested one.

Frequently asked questions

Do you need to cycle peptides?

We found no trial testing an on/off schedule for any peptide. Approved peptide medicines are dosed continuously according to their labels.

Does the body get used to peptides?

Receptors can desensitise, but in the growth hormone axis this happened within hours of continuous stimulation and the pituitary's reserve stayed intact.

How long can you take MK-677?

In a 12-month trial, IGF-1 was still 72.9% above baseline at a year of daily dosing; that trial missed its clinical endpoints and MK-677 is not approved.

Where did peptide cycling come from?

We found no peptide study that proposed or tested an on/off schedule; the schedules resemble anabolic steroid cycles, not anything in the receptor research.

Does switching between similar peptides reset anything?

In rat pituitary cells, two secretagogues of the same class desensitised the cells to each other, so swapping within a class is not a reset.

Sources

  1. Böhm, S. K., et al. (1997). Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J, 322 ( Pt 1)(Pt 1), 1-18. PMID: 9078236
  2. Vance, M. L., et al. (1986). Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH. J Clin Endocrinol Metab, 62(3), 591-4. PMID: 3080467
  3. Bowers, C. Y., et al. (1996). GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab, 9 Suppl 3, 261-70. PMID: 8887169
  4. Cheng, J., et al. (1997). Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci, 60(16), 1385-92. PMID: 9096259
  5. Sevigny, J. J., et al. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 71(21), 1702-8. PMID: 19015485
  6. Ortmann, O., et al. (2002). Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online, 5 Suppl 1, 1-7. PMID: 12537774
  7. Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, sections 2.1 and 5.2. DailyMed version 2; read October 27, 2026.
  8. Novo Nordisk. WEGOVY (semaglutide) US prescribing information, section 2.2. DailyMed version 19, effective June 18, 2026; read October 27, 2026.
  9. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 24(8), 1553-1564. PMID: 35441470

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead